Botulinum toxin is a powerful neurotoxin produced by Clostridium botulinum<\/em> and related bacteria. Uncontrolled exposure can cause botulism, but authorised botulinum toxin medicines contain carefully manufactured preparations intended for use at specific doses and for defined clinical purposes.<\/p>\n\n\n\n When injected into selected muscles, botulinum toxin reduces the release of acetylcholine, temporarily limiting muscle activity. This can help treat involuntary muscle contractions and soften expression lines, unlike dermal fillers, which add volume beneath the skin.<\/p>\n\n\n\n The history of botulinum toxin began with severe food poisoning linked to preserved or poorly prepared meat. In the early 19th century, German physician Justinus Kerner investigated these cases and recognised that the illness affected the nervous system and muscle function.<\/p>\n\n\n\n His detailed observations helped doctors understand botulism as a neurological illness, even though scientists could not yet identify the responsible bacterium or purify its toxin.<\/p>\n\n\n\n A major breakthrough came after a botulism outbreak in Belgium in 1895, linked to contaminated ham. Belgian microbiologist \u00c9mile Pierre-Marie van Ermengem investigated the outbreak and isolated the bacterium responsible, originally called Bacillus botulinus<\/em> and later renamed Clostridium botulinum<\/em>.<\/p>\n\n\n\n This discovery gave scientists a way to study botulism more systematically and investigate the toxin produced by the bacterium. Although this was far removed from modern cosmetic treatment, identifying the source and understanding its effects were essential steps towards developing botulinum toxin as a medicine.<\/p>\n\n\n\n Justinus Kerner did more than document food poisoning; he also considered how the toxin affected the nervous system. From the symptoms he observed, he suggested that it interfered with nerve signals and even proposed that controlled use might help conditions involving excessive nervous activity.<\/p>\n\n\n\n Kerner did not develop modern botulinum toxin injections, as purified toxin and suitable medical techniques did not yet exist. However, his early ideas helped establish a principle that later became central to medicine: a harmful substance can have therapeutic value when its dose and use are carefully controlled.<\/p>\n\n\n\n Identifying Clostridium botulinum<\/em> was only the beginning, as scientists needed to isolate and purify its toxin before it could be studied safely and consistently. During the first half of the 20th century, researchers, including microbiologist Edward Schantz, made important advances in producing purified botulinum toxin type A.<\/p>\n\n\n\n Reliable preparation was essential because doctors needed controlled doses and predictable effects before clinical use was possible. Schantz\u2019s work, followed by collaboration with ophthalmologist Alan B. Scott, helped move botulinum toxin from laboratory research towards medical treatment.<\/p>\n\n\n\n A major clinical breakthrough came through ophthalmologist Dr Alan B. Scott, who explored botulinum toxin as a treatment for strabismus. His research showed that carefully targeted injections could temporarily weaken an overactive eye muscle, offering a potential alternative to surgery.<\/p>\n\n\n\n After successful animal studies, Scott began treating patients with botulinum toxin type A in the late 1970s and published clinical results in 1980. This was a major milestone, showing that carefully targeted doses could temporarily alter muscle activity in people.<\/p>\n\n\n\n Scott continued developing botulinum toxin for conditions such as strabismus and blepharospasm, where reducing excessive muscle activity could improve symptoms. In 1989, the US Food and Drug Administration approved Scott\u2019s botulinum toxin type A product, then known as Oculinum, for strabismus and blepharospasm. Allergan acquired Oculinum in 1991; the product was subsequently renamed Botox.<\/p>\n\n\n\n This approval encouraged doctors to explore botulinum toxin for other medical conditions involving abnormal muscle activity. At this stage, cosmetic treatment was not the main focus, but observations of reduced facial lines during medical treatment would later help transform aesthetic medicine.<\/p>\n\n\n\n The cosmetic use of botulinum toxin began when doctors noticed that patients treated around the eyes and face for medical conditions sometimes developed fewer nearby facial lines. This made biological sense because repeated muscle movements from frowning, squinting or raising your eyebrows can contribute to expression lines.<\/p>\n\n\n\n Doctors gradually began exploring whether botulinum toxin could be used deliberately to improve facial appearance. An important early report came from Richard Clark and Craig Berris in 1989, when botulinum toxin was used to improve facial asymmetry caused by facial nerve paralysis. Although this was not a conventional anti-wrinkle treatment, it helped demonstrate that carefully weakening selected facial muscles could also alter facial appearance and symmetry.<\/p>\n\n\n\n Canadian physicians Jean and Alastair Carruthers played an important role in developing botulinum toxin as a cosmetic treatment. Jean was an ophthalmologist treating blepharospasm, while Alastair was a dermatologist, allowing them to explore how muscle-relaxing injections could also improve facial lines.<\/p>\n\n\n\n They began studying botulinum toxin specifically for glabellar frown lines and published an influential report in 1992. Their work helped shift botulinum toxin from an accidental cosmetic effect to a deliberate treatment for expression lines.<\/p>\n\n\n\n Interest in cosmetic botulinum toxin grew quickly during the 1990s as doctors studied different doses and injection sites. Clinical research increasingly focused on selecting doses and injection sites to reduce targeted muscle activity while limiting unwanted muscle weakness.<\/p>\n\n\n\n A major milestone came in 2002, when the US FDA approved Botox Cosmetic for temporary improvement of moderate to severe glabellar lines in suitable adults. Today, several authorised botulinum toxin products exist, and their doses are not automatically interchangeable, so treatment must be tailored to the specific product.<\/p>\n\n\n\nWhere Did the Story of Botulinum Toxin Begin?<\/strong><\/h2>\n\n\n\n
The 1895 Outbreak That Changed Botulism Research<\/strong><\/h2>\n\n\n\n
Why Was Justinus Kerner So Important to Its Medical Future?<\/strong><\/h2>\n\n\n\n
![\"\"](\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/08\/Imagess-2026-08-18T023933.551.jpg\")
<\/figure>\n\n\n\nHow Did Scientists Turn a Poison into a Research Tool?<\/strong><\/h2>\n\n\n\n
How Did Alan Scott Change the Future of Botulinum Toxin?<\/strong><\/h2>\n\n\n\n
From Eye-Muscle Treatment to an Approved Medicine<\/strong><\/h2>\n\n\n\n
How Was the Cosmetic Effect First Noticed?<\/strong><\/h2>\n\n\n\n
How Did Jean and Alastair Carruthers Influence Cosmetic Dermatology?<\/strong><\/h2>\n\n\n\n
When Did Botulinum Toxin Become an Established Cosmetic Treatment?<\/strong><\/h2>\n\n\n\n
From Poison to Cosmetic Treatment: A Botulinum Toxin Timeline<\/strong><\/h2>\n\n\n\n
![\"\"](\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/08\/Imagess-2026-08-18T024105.457-1024x559.jpg\")
<\/figure>\n\n\n\n![\"\"](\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/08\/Imagess-2026-08-18T024604.567.jpg\")
<\/figure>\n\n\n\n